Brokerage : Hana Securities
Analyst : Seona Kim (RA: Changkeun Yoo)
Investment Rating : BUY (Maintained)
Target Price : KRW 2,050,000 (Maintained)
Core Momentum : Full capacity operation at Plant 4 combined with the scheduled Q3 revenue recognition from the newly operating Rockville facility and the potential upward revision of full-year corporate guidance.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY (Maintained) / Target Price (12M) KRW 2,050,000 (Maintained) (Derived using a target EV/EBITDA multiple of 36.6x, applying a 2.3x premium over Lonza’s FY1 EV/EBITDA applied to 2027E EBITDA discounted at WACC 8.8%; closing price as of April 22, 2026: KRW 1,561,000)
- Market Data: KOSPI Index 6,417.93pt / Market Cap KRW 72.26 Trillion / Shares Outstanding 46,291,000 / Foreign Ownership 12.62% / Major Shareholders: Samsung C&T and 5 affiliates 74.31%, National Pension Service 6.68%
- Annual Financial Forecast (Hana Securities Estimates):
- 2026F: Revenue KRW 5.34 Trillion (+17.2% YoY), Operating Profit KRW 2.42 Trillion (+17.1% YoY), OPM 45.3%, Pre-tax Profit KRW 2.57 Trillion, Net Profit KRW 1.94 Trillion, EPS KRW 41,886, BPS KRW 225,892, PER 37.27x, PBR 6.91x, ROE 20.21%, EV/EBITDA 25.25x
- 2027F: Revenue KRW 5.62 Trillion, Operating Profit KRW 2.54 Trillion, OPM 45.2%, Pre-tax Profit KRW 2.73 Trillion, Net Profit KRW 2.07 Trillion, EPS KRW 44,798, BPS KRW 270,612, PER 34.85x, PBR 5.77x, ROE 19.97%, EV/EBITDA 23.80x
🚀 2. [Market Opportunities & Business Outlook]
- Q1 2026 Earnings Performance:
- Consolidated revenue reached KRW 1.26 Trillion (+25.8% YoY) and operating profit came in at KRW 580.7 Billion (+35.1% YoY, OPM 46.2%), aligning closely with consensus estimates (Revenue KRW 1.28 Trillion, OP KRW 590.2 Billion).
- High USD/KRW exchange rate levels and continuous 100% utilization of Plant 4 supported performance, while effective cost management was maintained as corporate split and Rockville-related expenses were mostly absorbed in Q4 2025.
- Rockville Site Integration & Guidance Upside Potential:
- The 60,000-liter Rockville manufacturing asset (acquisition completed late March) begins operations in Q2, with commercial revenue recognition set for Q3. Currently operating at ~50% capacity utilization, the site is estimated to contribute an additional ~5% increase to annual guidance (~KRW 250B–300B in revenue) while sustaining mid-40% OPM.
- Baseline 2026 guidance (revenue growth +15–20%, OPM mid-40%) is comfortably achievable under an assumed average FX rate of 1,450 KRW/USD even before incorporating Rockville contributions.
- Plant 5 Commercialization Roadmap & CAPEX Expansion:
- Plant 5 is currently producing process performance qualification (PPQ) batches with minimal fixed-cost ramp-up headwinds, with full-scale commercial manufacturing revenues expected to materialize in mid-2027.
- The easing of tariff uncertainties and potential CAPEX expansion (Rockville site additions and Plant 6 groundbreaking) provide structural catalysts for upward adjustments to future earnings estimates and valuation multiples.
📝 Editor’s Comment (Perspective)
The analyst views Samsung Biologics as a leading global CDMO positioned to substantiate its valuation premium over global peers, anchored by stable profitability from Plant 4 full utilization and strategic geographical expansion through the Rockville acquisition. The overarching perspective focuses on the upcoming revenue integration of the US Rockville site in Q3 and the resulting upside potential to full-year corporate guidance, rather than marginal variances in backward-looking quarterly results.
To verify whether this investment thesis progresses as expected, investors should primarily monitor the actual top-line contribution from the Rockville facility disclosed in Q3 earnings, the formal revision scale of annual corporate guidance, the timeline for Plant 5 transitioning from PPQ batches to commercial delivery in 2027, and updates regarding Plant 6 CAPEX execution. These developments can be verified through future quarterly earnings releases, official company IR presentations, and regulatory filings on DART/KRX.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
